JP2007509982A - 血漿コレシストキニン（ｃｃｋ）濃度を制御するための非膵臓プロテアーゼおよび痛みを処置するための非膵臓プロテアーゼ - Google Patents

血漿コレシストキニン（ｃｃｋ）濃度を制御するための非膵臓プロテアーゼおよび痛みを処置するための非膵臓プロテアーゼ Download PDF

Info

Publication number
JP2007509982A
JP2007509982A JP2006538382A JP2006538382A JP2007509982A JP 2007509982 A JP2007509982 A JP 2007509982A JP 2006538382 A JP2006538382 A JP 2006538382A JP 2006538382 A JP2006538382 A JP 2006538382A JP 2007509982 A JP2007509982 A JP 2007509982A
Authority
JP
Japan
Prior art keywords
protease
mammal
pancreatic
cck
administration
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2006538382A
Other languages
English (en)
Japanese (ja)
Other versions
JP2007509982A5 (cg-RX-API-DMAC10.html
Inventor
アレクセイ エル． マーゴリン，
バーミ シー． シェノイ，
マーガレット マグラス，
Original Assignee
アルタス ファーマシューティカルズ インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アルタス ファーマシューティカルズ インコーポレイテッド filed Critical アルタス ファーマシューティカルズ インコーポレイテッド
Publication of JP2007509982A publication Critical patent/JP2007509982A/ja
Publication of JP2007509982A5 publication Critical patent/JP2007509982A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4826—Trypsin (3.4.21.4) Chymotrypsin (3.4.21.1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Zoology (AREA)
  • Pain & Pain Management (AREA)
  • Nutrition Science (AREA)
  • Rheumatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
JP2006538382A 2003-10-29 2004-10-29 血漿コレシストキニン（ｃｃｋ）濃度を制御するための非膵臓プロテアーゼおよび痛みを処置するための非膵臓プロテアーゼ Pending JP2007509982A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US51555203P 2003-10-29 2003-10-29
US52749003P 2003-12-05 2003-12-05
PCT/US2004/036228 WO2005042012A1 (en) 2003-10-29 2004-10-29 Non-pancreatic proteases for controlling plasma cholecystokinin (cck) concentration and for treating pain

Publications (2)

Publication Number Publication Date
JP2007509982A true JP2007509982A (ja) 2007-04-19
JP2007509982A5 JP2007509982A5 (cg-RX-API-DMAC10.html) 2007-11-15

Family

ID=34556008

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2006538382A Pending JP2007509982A (ja) 2003-10-29 2004-10-29 血漿コレシストキニン（ｃｃｋ）濃度を制御するための非膵臓プロテアーゼおよび痛みを処置するための非膵臓プロテアーゼ

Country Status (9)

Country Link
US (2) US7459155B2 (cg-RX-API-DMAC10.html)
EP (1) EP1682168B1 (cg-RX-API-DMAC10.html)
JP (1) JP2007509982A (cg-RX-API-DMAC10.html)
KR (1) KR20060127857A (cg-RX-API-DMAC10.html)
AU (1) AU2004285558A1 (cg-RX-API-DMAC10.html)
CA (1) CA2544156C (cg-RX-API-DMAC10.html)
ES (1) ES2421538T3 (cg-RX-API-DMAC10.html)
IL (1) IL175210A (cg-RX-API-DMAC10.html)
WO (1) WO2005042012A1 (cg-RX-API-DMAC10.html)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007222169A (ja) * 2006-02-24 2007-09-06 Dade Behring Marburg Gmbh セリンエンドペプチダーゼの安定化調製物、その製造および使用
JP2013505255A (ja) * 2009-09-17 2013-02-14 アプタリス ファーマテク，インコーポレイテッド 膵炎及び膵不全を治療するための膵酵素組成物及び方法

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1319655B1 (it) 2000-11-15 2003-10-23 Eurand Int Microsfere di enzimi pancreatici con elevata stabilita' e relativometodo di preparazione.
US20090175842A1 (en) * 2006-07-11 2009-07-09 Chandrakant Laxminarayan Rathi Dietary anti-bacterial compositions
PT2079445E (pt) 2007-02-20 2016-02-29 Allergan Pharmaceuticals Internat Ltd Composições de enzimas digestivas estáveis
WO2009109856A2 (en) 2008-03-07 2009-09-11 Axcan Pharma Inc. Method for detecting infectious parvovirus in pharmaceutical preparations
WO2011126811A2 (en) 2010-03-30 2011-10-13 Pfenex Inc. High level expression of recombinant toxin proteins
EA029101B1 (ru) 2010-10-01 2018-02-28 Апталис Фарма Лимитид Составы с низкой дозой панкрелипазы и кишечнорастворимым покрытием
WO2012155027A1 (en) 2011-05-12 2012-11-15 Healthpoint, Ltd. Wound debridement compositions containing seaprose and methods of wound treatment using same
CA2843556A1 (en) 2011-08-08 2013-02-14 Aptalis Pharma Ltd. Method for dissolution testing of solid compositions containing digestive enzymes
US20130156884A1 (en) * 2011-12-19 2013-06-20 Triarco Industries Protease enzymes for increased protein digestion rate and absorption and methods of using the same
US9962430B2 (en) 2012-02-15 2018-05-08 Chirhoclin, Inc. Methods for treating pain associated with chronic pancreatitis
KR20150013280A (ko) * 2012-05-11 2015-02-04 스미스 앤드 네퓨, 인크. 박테리아 균막을 제거하기 위한 세아프로제의 용도
US11406718B2 (en) 2012-05-29 2022-08-09 Chirhoclin, Inc. Methods of detecting pancreobiliary ductal leaks
EP3639846B1 (en) 2013-08-09 2022-09-28 Allergan Pharmaceuticals International Limited Digestive enzyme composition suitable for enteral administration
SG11201602012RA (en) 2013-09-25 2016-04-28 Pronutria Inc Compositions and formulations for maintaining and increasing muscle mass, strength, and performance and methods of production and use thereof
EP3157568A1 (en) 2014-06-19 2017-04-26 Aptalis Pharma Limited Methods for removing viral contaminants from pancreatic extracts
WO2018020435A1 (en) 2016-07-27 2018-02-01 Smith & Nephew, Inc. Use of thermolysin to reduce or eliminate bacterial biofilms from surfaces
US11413300B2 (en) 2017-01-30 2022-08-16 Smith & Nephew, Inc. Synergistic combination of thermolysin and an antibacterial agent to reduce or eliminate bacterial biofilms from surfaces
US11744878B2 (en) 2020-08-19 2023-09-05 Chirhoclin, Inc. Methods for treatment of COVID-19 syndrome
EP4369942A1 (en) 2021-07-12 2024-05-22 Zidkiyahu Simenhaus Protein containing bio-active compositions comprising cellulose microparticle carriers

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS61293927A (ja) * 1986-06-18 1986-12-24 Kaken Pharmaceut Co Ltd 肝臓疾患予防治療剤
JPS62215533A (ja) * 1986-03-17 1987-09-22 Shigemi Fujisaki 膠原病又は関節リウマチの予防治療剤
JPH01132533A (ja) * 1987-11-18 1989-05-25 Toa Yakuhin Kogyo Kk 動物用薬剤
JPH01238538A (ja) * 1988-03-18 1989-09-22 Toa Yakuhin Kogyo Kk 健胃消化剤
WO2002036156A1 (de) * 2000-11-02 2002-05-10 Cilian Ag Verwendung von aus ciliaten gewonnenen enzymen als verdauungsfördernde arzneimittel
JP2003524421A (ja) * 2000-02-24 2003-08-19 アルタス バイオロジックス インコーポレイテッド リパーゼ含有組成物およびこれらの使用方法

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2129947A1 (en) 1971-03-23 1972-11-03 Amano Pharma Co Ltd Anti-inflammatory protease prepn - from aspergillus
JPS5692217A (en) * 1979-12-26 1981-07-25 Kowa Co Easily absorbable enzyme preparation
JPS5826822A (ja) * 1981-08-10 1983-02-17 Kaken Pharmaceut Co Ltd 慢性腎炎治療剤
JPS608225A (ja) * 1983-06-29 1985-01-17 Kowa Co 腸管吸収医薬組成物
JPH02292226A (ja) 1989-05-08 1990-12-03 Shigemi Fujisaki 障害された神経細胞賦活予防治療剤
US5514373A (en) * 1992-05-22 1996-05-07 Harris, Jr.; Roosevelt D. Topical preparation
US5628981A (en) * 1994-12-30 1997-05-13 Nano Systems L.L.C. Formulations of oral gastrointestinal diagnostic x-ray contrast agents and oral gastrointestinal therapeutic agents
WO1998036734A1 (en) 1997-02-21 1998-08-27 Beth Israel Deaconess Medical Center Inc. A novel nutritional therapy which minimizes plasma cholecystokinin (cck) levels
JPH1149699A (ja) 1997-08-01 1999-02-23 Masao Igarashi 女性慢性下腹疼痛症候群治療剤
US6413512B1 (en) * 1998-02-13 2002-07-02 National Enzyme Company Composition and method for treating disease by increasing activated α2 macroglobulin in the blood and extravascular tissue
US6638906B1 (en) * 1999-12-13 2003-10-28 Nobex Corporation Amphiphilic polymers and polypeptide conjugates comprising same
AR032392A1 (es) * 2001-01-19 2003-11-05 Solvay Pharm Gmbh Mezcla de enzimas, preparado farmaceutico y utilizacion de dicho preparado.
US20030026794A1 (en) * 2001-07-31 2003-02-06 Howard Fein Selective enzyme treatment of skin conditions
US6713096B2 (en) * 2002-01-04 2004-03-30 Melaleuca, Inc. Dietary supplements and methods for treating pain and inflammation
US20040038874A1 (en) * 2002-08-22 2004-02-26 Osemwota Omoigui Method of treatment of persistent pain

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS62215533A (ja) * 1986-03-17 1987-09-22 Shigemi Fujisaki 膠原病又は関節リウマチの予防治療剤
JPS61293927A (ja) * 1986-06-18 1986-12-24 Kaken Pharmaceut Co Ltd 肝臓疾患予防治療剤
JPH01132533A (ja) * 1987-11-18 1989-05-25 Toa Yakuhin Kogyo Kk 動物用薬剤
JPH01238538A (ja) * 1988-03-18 1989-09-22 Toa Yakuhin Kogyo Kk 健胃消化剤
JP2003524421A (ja) * 2000-02-24 2003-08-19 アルタス バイオロジックス インコーポレイテッド リパーゼ含有組成物およびこれらの使用方法
WO2002036156A1 (de) * 2000-11-02 2002-05-10 Cilian Ag Verwendung von aus ciliaten gewonnenen enzymen als verdauungsfördernde arzneimittel

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
EL-BOHY,A. ET AL: "Deafferentation-induced changes in neuropeptides of the adult rat dorsal horn following pronase inje", J COMP NEUROL, vol. 336, no. 4, JPN6010044210, 1993, pages 545 - 54, ISSN: 0001690159 *
VENTRUCCI,M. ET AL: "[Therapeutic effect of a pharmacologic combination of choleretics and digestive enzymes in exocrine", MINERVA MED, vol. 66, no. 17, JPN6010044209, 1975, pages 819 - 23, ISSN: 0001690157 *
メルクマニュアル第17版日本語版, JPN6010044212, 1999, pages 272 - 278, ISSN: 0001690158 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007222169A (ja) * 2006-02-24 2007-09-06 Dade Behring Marburg Gmbh セリンエンドペプチダーゼの安定化調製物、その製造および使用
JP2013505255A (ja) * 2009-09-17 2013-02-14 アプタリス ファーマテク，インコーポレイテッド 膵炎及び膵不全を治療するための膵酵素組成物及び方法

Also Published As

Publication number Publication date
IL175210A0 (en) 2006-09-05
CA2544156C (en) 2012-07-10
KR20060127857A (ko) 2006-12-13
US20050158299A1 (en) 2005-07-21
ES2421538T3 (es) 2013-09-03
US20090081184A1 (en) 2009-03-26
AU2004285558A1 (en) 2005-05-12
CA2544156A1 (en) 2005-05-12
WO2005042012A1 (en) 2005-05-12
EP1682168A1 (en) 2006-07-26
US7459155B2 (en) 2008-12-02
IL175210A (en) 2014-02-27
EP1682168B1 (en) 2013-05-01

Similar Documents

Publication Publication Date Title
US20090081184A1 (en) Non-pancreatic proteases for controlling plasma cholecystokinin (cck) concentration and for treating pain
CN101068565B (zh) 治疗胰腺功能不全的包含脂酶、蛋白酶和淀粉酶的组合物
US9233146B2 (en) Method of treating and diagnosing Parkinson's disease and related dysautonomic disorders
AU2014229330B2 (en) Composition containing digestive enzymes and nutrients suitable for enteral administration
US11124785B2 (en) Rothia subtilisins, S8A family proteases, as therapeutic enzymes for application in gluten intolerance disorders
Szkopek et al. A review: Pancreatic enzymes in the treatment of chronic pancreatic insufficiency in companion animals
IL274583A (en) Pancreatin pharmacological preparations with high potency
US20180104317A1 (en) Methods and pharmaceutical compositions for treating celiac disease and gluten intolerance
CN102883712A (zh) 耐胃液酶药物组合物
AU2002223666B2 (en) Use of enzymes obtained from ciliates as medicaments for promoting digestion
US20030095961A1 (en) Composition and method for treating disease by increasing activated alpha2 macroglobulin in the blood and extravascular tissue
EP0387945A1 (en) A composition for the treatment of exocrine insufficiency of the pancreas, and the use of said composition
RU2068698C1 (ru) Лекарственное средство для лечения больных со сниженной внешнесекреторной функцией поджелудочной железы
HK1109068B (en) Compositions containing lipase; protease and amylase for treating pancreatic insufficiency
WO2022195152A1 (es) Sistema de administración en múltiples sitios para administración diferencial en el tracto gastrointestinal
Mössner et al. Does feedback regulation exist in chronic pancreatitis?
MÖSSNER Does Feedback Regulation Exist
JPH11189544A (ja) 消化酵素含有医薬品
RS55450B1 (sr) Kompozicije koje sadrže lipazu, proteazu i amilazu za lečenje pankreatične insuficijencije
HK1145462B (en) Compositions containing lipase, protease and amylase for treating pancreatic insufficiency

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20070920

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20070920

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20100803

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20101101

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20110210